Our new preprint on the efficacy of a single dose of the Oxford/AZ ChAdOx1 nCoV-19 #vaccine-76% efficacy against symptomatic infection from day 22 to day 90 post vaccination in 17,177 trial participants in UK, Brazil and S Africa:
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268 …
-
-
Clear relationship between binding and neutralising antibody response at 28 days post dose 2 and vaccine efficacy (VE) with 12+ week interval given strongest antibodies and higher VEpic.twitter.com/OIvmDtn2pN
Show this thread -
No-one in a population of 12,408 people vaccinated with a single dose of ChAdOx1 nCo-19 was hospitalised with COVID-19 from 22 days after immunisation. This is the most important thing! 76% efficacy against symptomatic COVID-19 is great, but 0 people hospitalised is everything.pic.twitter.com/4Q4iXTH6lN
Show this thread -
Finally, reduction in any PCR+ (symptomatic or asymptomatic) of 54% after 2 doses, indicating the potential for reducing transmission. Overall, the Oxford/AZ vaccine has 76% efficacy against symptomatic COVID19 infection, prevents hospitalisation and reduces transmission!
Show this thread -
#VaccinesWork (but also still please stay at home, wear a mask, social distance, wash your hands and be nice to each other)!Show this thread
End of conversation
New conversation -
-
-
Great stuff. More data soon please so our European friends like Macron can obtain new insights to replace their current ones......
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
How do you explain low VE (25%) @ 40 days?
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.